when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ROCHE · news · pharmadog

← back to ROCHE

News mentioning ROCHE

262 stories

May 8, 26Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Canceronclive

May 8, 26Spain readies for evacuations as a hantavirus-hit cruise ship heads for the Canary Islandsstat

May 8, 26STAT+: Roche to buy PathAI for $750 millionstat

May 8, 26Lilly to invest extra $4.5B across Indiana manufacturingbiopharma dive

May 7, 26Entrada stock falls on Duchenne data; Wegovy expands accessendpoints

May 7, 26Roche to acquire digital pathology firm PathAI in deal potentially worth over $1Bbiopharma dive

May 6, 26Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive

May 6, 26Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipelinebiopharma dive

May 4, 26Celcuity strengthens case for ASCO-spotlighted breast cancer drugbiopharma dive

May 1, 26Arvinas’ ‘Protac’ breast cancer drug cleared by FDAbiopharma dive

Apr 30, 26Avalyn, in pursuit of better lung drugs, banks $300M in an IPObiopharma dive

Apr 28, 26Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.biopharma dive

Apr 27, 26STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and morestat

Apr 24, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Apr 24, 26Sanofi MS drug rejected in US gets an endorsement in Europebiopharma dive

Apr 24, 26STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and morestat

Apr 23, 26STAT+: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boardsstat

Apr 23, 26Roche, facing biosimilar threats, puts faith in new cancer and obesity drugsbiopharma dive

Apr 23, 26Roche says its investigational breast cancer pill could outsell Herceptinendpoints

Apr 22, 26Merck adds to pharma’s AI push; Roche details MS drug resultsbiopharma dive

Dec 23, 25Fierce Biotech Layoff Tracker 2026: Foghorn cuts workforce by 40%; BioMarin drops 117 rolesfiercebiotech

Dec 22, 25Fierce Biotech Fundraising Tracker '26: KymaThera corrals $80M; RougeTx lifts off with $58Mfiercebiotech

← prevpage 9 of 9next →